FDA looks to foster generics competition

A recent Food and Drug Administration public meeting kicked off a two-month comment period during which stakeholders have been encouraged to share their input on how best to improve generic competition and what current barriers exist.

Want to Read More?

This content is available only to registered users. Log in to read the rest of this article or create a free account.

Login or Register to post a comment.